Asia-Pacific companies are spearheading innovation in the idiopathic thrombocytopenic purpura pipeline

1 May 2020 (Last Updated May 1st, 2020 09:58)

Idiopathic thrombocytopenic purpura is a blood disorder identified by the generation of antibodies that bind to platelets, provoking symptoms such as epistaxis, menorrhagia in women, and the development of petechiae. Serious complications can include intraperitoneal or intracerebral haemorrhage, which most commonly occurs when the platelet count is below 5,000 per μl.

There are five first-in-class products in clinical development for idiopathic thrombocytopenic purpura therapy, all of which target proteins not acted upon by any commercially available marketed drugs. Read more here.